Loading
Heidelberg Pharma
Heidelberg Pharma is a German company building antibody-drug conjugates around amanitin, a toxin from the death cap mushroom that kills cells by blocking RNA polymerase II, with its lead candidate HDP-101 in multiple myeloma.
Also called: Heidelberg Pharma AG
Overview
Heidelberg Pharma, based in Ladenburg near Heidelberg and listed in Frankfurt, develops antibody-targeted amanitin conjugates (ATACs): the payload amanitin inhibits RNA polymerase II, a mechanism distinct from the microtubule and DNA-damaging payloads of most ADCs and active in slowly dividing cells. Its lead candidate HDP-101 targets BCMA in relapsed multiple myeloma, and the platform is licensed to partners including Takeda. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov, from earlier programmes.
Connected
6Similar pages
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Takeda, Multiple myeloma.
- TrialHuman BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
Shares BCMA, Multiple myeloma.
- TrialA Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
Shares Takeda, Antibody-drug conjugate (ADC).
- CompanyCartesian Therapeutics
Shares BCMA, Multiple myeloma.
- TreatmentAZD4045
Shares BCMA, Multiple myeloma.
- CompanyKelonia Therapeutics
Shares BCMA, Multiple myeloma.
- PersonNoopur Raje
Shares BCMA, Multiple myeloma.
- CompanyAurigene Oncology
Shares BCMA, Multiple myeloma.
cancers
fronts
technologies
targets
companies
trials
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
heidelberg-pharma.com · 1
Wikipedia · 1
A source that has moved or gone is reported by the weekly link check. /audit/